Effects of Magnesium Sulfate Therapy on GCS Scores in Patients with Severe Traumatic Brain Injury
Objective: Traumatic brain injury (TBI) is the number one cause of death under 44 years of age; in spite of this fact, there is no standard available pharmacological agent for the treatment of brain injury. We evaluated the effectiveness of magnesium sulfate treatment for the management and outcome of TBI.
Material and Methods: The prospective cases (n = 60) of TBI were included with non-probability consecutive sampling. They received standard protocol treatment for TBI and magnesium sulfate as an add on therapy. GCS was noted on two occasions, at the time of admission and on the 3rd day. T-test was used to compare the results and for identification of significance/insignificance results.
Results: Mean age of the patients was 37.12 ± 13.25 years. Majority were male (68.3%), while females were 31.7%. Mean duration of an elapsed post traumatic brain injury was 5.06 ± 2.32 hours. Mean GCS before magnesium sulfate treatment (on admission) was 5.46 ± 1.521; mean Glasgow coma (GCS) after magnesium sulfate treatment (on 3rd day) was 8.03 ± 2.56. There existed a significant difference between the GCS scores at the time of admission and on 3rd day (p value < 0.0001). Mean GCS was 7.69 ± 2.55 in age < 30 years and it was 8.29 ± 2.57 in age > 30 years, but this difference was not statistically significant.
Conclusion: A significant improvement was found in the GCS after magnesium sulfate therapy in patients with TBI.
2. Mosenthal AC, Lavery RF, Addis M, Kaul S, Ross S, Marburger R, Deitch EA, Livingston DH. Isolated traumatic brain injury: age is an independent predictor of mortality and early outcome. Journal of Trauma and Acute Care Surgery, 2002; 52 (5): 907-11.
3. Rapoport MJ, Feinstein A. Outcome following traumatic brain injury in the elderly: a critical review. Brain Injury, 2000; 14 (8): 749-61.
4. Li W, Bai YA, Li YJ, Liu KG, Wang MD, Xu GZ, Shang HL, Li YF. Magnesium sulfate for acute traumatic brain injury. J Craniofac Surg. 2015; 26 (2): 393-8.
5. Busingye DS, Turner RJ, Vink R. Combined Magnesium/Polyethylene Glycol Facilitates the Neuroprotective effects of magnesium in traumatic brain injury at a reduced magnesium dose. CNS Neuroscience & Therapeutics, 2016; 22: 854–859.
6. Herrera-Melero MC, Egea-Guerrero JJ, Vilches-Arenas A, Rincón-Ferrari MD, Flores-Cordero JM, León-Carrión J, Murillo-Cabezas F. Acute predictors for mortality after severe TBI in Spain: Gender differences and clinical data. Brain Injury, 2015; 29 (12): 1439-44.
7. Zhao L, Wang W, Zhong J, Li YY, Cheng YZ, Su Z,
et al. The effects of magnesium sulfate therapy after severe diffuse axonal injury. Ther Clin Risk Manag. 2016; 12: 1481–1486.
8. Haring RS, Narang K, Canner JK, et al. Traumatic brain injury in the elderly: morbidity and mortality trends and risk factors. J Surg Res. 2015; 10: 750-756.
9. Gennarelli TA, Thibault LE, Adams JH, Graham DI, Thompson CJ, Marcincin RP. Diffuse axonal injury and traumatic coma in the primate. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 1982; 12 (6): 564-74.
10. Mac Donald CL, Johnson AM, Cooper D, Nelson EC, Werner NJ, Shimony JS, et al. Detection of blast-related traumatic brain injury in U.S. military personnel. N Engl J Med. 2011; (22): 2091-100.